Abstract:Background Several chimeric antigen receptor T cells (CAR T) targeting CD19 have induced profound and prolonged remission for refractory/relapsed (R/R) B-cell lymphoma. The risk of secondary malignancies, especially myeloid neoplasms, is of particular concern in the CAR T community, which still remains unclear. Methods Four patients with R/R B-cell lymphoma after CD19 CAR T therapy diagnosed with secondary myeloid neoplasms (SMN) from 2 hospitals in eastern China were presented, including 3 with myelodysplastic syndrome (MDS) and 1 with acute myeloid leukemia (AML). Using single-cell RNA sequencing (scRNA-seq), we compared the cellular components of bone marrow (BM) samples obtained from one of these MDS patients and a health donor. We also provided a review of recently published literature concerning SMN risk of CAR T therapy. Results Relevant demographic, clinical, laboratory, therapeutic and outcome data were collected and presented by chart review. In our case series, the male-female ratio was 3.0 and the median age at MDS onset was 61.25 years old (range, 50-78). Median number of previous systemic therapies was 4.5 (range, 4-5), including autologous hematopoietic stem cell transplantation (auto-HSCT) in one patient. BM assessments prior to CAR T therapy confirmed normal hematopoiesis without myeloid neoplasms. Moreover, for 3 patients with SMN in our series, cytogenetic analysis predicted a relatively adverse outcome. In our experience and in the literature, treatment choices for the patients with SMN included allogeneic hematopoietic stem cell transplantation (allo-HSCT), hypomethylating agent (HMA), period filgrastim, transfusions and other supportive care. Finally, treatment responses of lymphoma, together with SMN, directly correlated with the overall survival of this community. Of note, it appeared that pathogenesis of MDS wasn’t associated with the CAR T toxicities, since all 4 patients experienced a pretty mild CRS of grade 1-2. Additionally, scRNA-seq analysis described the transcriptional alteration of CD34+ cells, identified 13 T/NK clusters, and also indicated increased cytotoxic T cells in MDS BM. Conclusion Our study illustrated the onset and progression of SMN after CD19 CAR T therapy in patients with R/R B-cell lymphoma, which provides useful information of this uncommon later event.

The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?

Secondary Myeloid Neoplasms after CD19 CAR T Therapy in Patients with Refractory/relapsed B-cell Lymphoma: Case Series and Review of Literature

CAR T-cell immunotherapy of B-cell malignancy: the story so far

Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients

Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma

Long-term outcomes following CAR T cell therapy: what we know so far

Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice

Current Status of CAR T Cell Therapy for Leukemias

Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies

Immunogenicity of CAR T cells in cancer therapy

Low risk of CAR T cells going rogue

Current understanding and management of CAR T cell-associated toxicities

Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review

Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma

Evolving strategies for addressing CAR T-cell toxicities

Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies

Current state of CAR-T therapy for T-cell malignancies